DXCM · DexCom, Inc.

Current Thesis

DexCom is the leader of a freshly re-accelerating CGM narrative coming off a beaten-down base. The June ADA Scientific Sessions (6/5–8) gave the story a stage, and two structural catalysts landed inside a week: the CONNECT trial (reported 6/8) showed the G7 cut A1C by 1.6% over 26 weeks in Type 2 patients not on insulin the largest untapped CGM population and the FDA cleared the first OTC continuous glucose monitor for children (6/12), opening a new cash-pay demographic. Sell-side is chasing: Stifel ($90, 6/5), Mizuho ($85, 6/9) and TD Cowen ($95, 6/10) all raised targets in six sessions. The theme reads ACCELERATING. The catch is structural this is a recovery bounce trading below the 200-EMA on sub-average volume, so a fresh entry at current levels is buying extension after the pop rather than a confirmed breakout.

Bull Case

• TAM expansion is now data-backed. CONNECT trial (6/8): G7 delivered a 1.6% average A1C reduction over 26 weeks in Type 2 patients not using insulin. That cohort tens of millions of US adults is the CGM market's biggest unpenetrated layer beyond the insulin-using base already served.
• First OTC pediatric CGM clearance (6/12). New demographic, retail/cash-pay channel, and brand reach that doesn't depend on the prescription funnel.
• Analyst cluster confirms acceleration. Three target raises in six sessions Stifel Buy $90 (6/5), Mizuho Outperform $85 (6/9), TD Cowen Buy $95 (6/10) is the kind of clustering that front-runs a broader re-rating.
• ADA stage + "strategic business initiatives" (6/4 announcement). Management used the highest-visibility diabetes venue to frame the Type 2 growth story (corroborated by the 6/8 "Clinical Wins Boost Dexcom Growth Story" coverage).

Bear Case

• Bounce, not breakout. The 50-EMA sits below the 200-EMA, price is under the 200-EMA, and the advance ran at roughly 0.74x average volume. Buyers have not confirmed; the move is reclaiming overhead supply from the prior breakdown.
• Abbott Libre is the other horse in a pricing war. Any Libre share/price headline, or a loss of pump-integration slots with Insulet/Tandem, snaps an unconfirmed advance quickly.
• A1C data ≠ reimbursement. The Type 2 non-insulin TAM only monetizes when payers cover it, and coverage typically lags clinical wins by several quarters.
• The easy leg already ran. RSI tagged the high-70s into the ADA peak before cooling. Targets of $85–95 sit only modestly above the high-the published invalidation levels tape, so reward/risk on a fresh chase is compressed.

Setup & Price Structure

• Reclaimed the high-the published invalidation levels on the ADA-driven run; RSI cooled from the high-70s back toward the low-60s momentum digesting, not breaking.
• Support: the the published invalidation level–71 shelf (round number plus recovery base) is the line that defines the bounce. Lose it and the move is over.
• Resistance: overhead supply from the prior gap-down zone, with the 200-EMA as the specific level that converts "bounce" into "trend."
• Volume tell: the advance ran near 0.74x average the missing confirmation. A 200-EMA reclaim on expanding volume is the signal that the recovery has turned into a trend rather than a counter-trend pop.

Catalyst Calendar (next 30 days)

• No hard dated binary inside the window. The narrative drivers have already printed: ADA (6/5–8), CONNECT data (6/8), OTC pediatric clearance (6/12).
• Ongoing, undated: further analyst target revisions extending the $85→$90→$95 cluster; the OTC pediatric commercial rollout (no firm launch date disclosed).
• Next binary beyond the window: Q2 2026 earnings, expected ~late July 2026 the print that tests whether ADA enthusiasm translates into Type 2 unit adds and a guidance raise. Avoid a fresh chase into that print once the date is set.

What Would Change Our Mind

• Bullish confirmation: a daily close above the 200-EMA on >1.3x volume, ideally paired with a fresh upgrade (not just a target bump) that flips the read from recovery bounce to trend and justifies adding.
• Bearish invalidation: a daily close below ~the published invalidation level or a weekly close back under the 20-EMA either marks the unconfirmed bounce as failed; stand aside and wait for a cleaner base.
• Narrative break: an Abbott Libre price/share headline, a pump-partner integration loss, or the medtech theme losing ACCELERATING status.

Correlation Notes

• Trades inside the diabetes-tech cluster with Abbott (Libre, the direct CGM rival) and pump partners Insulet (PODD) and Tandem (TNDM); DexCom is the cluster leader on the CGM narrative.
• High-multiple medtech growth makes it loosely rate-sensitive a sharp backup in yields pressures the whole group's valuation.
• GLP-1 cross-current: the CONNECT Type 2 non-insulin data is a direct rebuttal to the 2023–24 "GLP-1 displaces CGM" bear thesis (Lilly/Novo). The name tends to trade inversely to acute GLP-1-displacement fears, so GLP-1 adoption headlines cut both ways.